Online Inquiry

BrCH2CONH-PEG6-acid

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Category	BrCH2CONH-PEGn-acid
Catalog NO.	BPG-1316
Product Name	BrCH2CONH-PEG6-acid
CAS	1609108-71-5
Molecular Formula	C17H32BrNO9
Molecular Weight	474.35

Scheme Design
Custom Synthesis
cGMP Manufacturing
Quality Assurance

Product Information
Application
References
Documents
Reviews

Product Information

Description	BrCH2CONH-PEG6-acid is a PEG linker containing a bromide group and a terminal carboxylic acid. The bromide (Br) is a very good leaving group for nucleophilic substitution reactions. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. The hydrophilic PEG spacer increases solubility in aqueous media.
Synonyms	Bromoacetamido-PEG6-C2-acid; Bromoacetamido-PEG6-CH2CH2COOH; Bromoacetamido-PEG6-acid; 1-bromo-2-oxo-6,9,12,15,18,21-hexaoxa-3-azatetracosan-24-oic acid; Propanoic acid, 3-[(20-bromo-19-oxo-3,6,9,12,15-pentaoxa-18-azaeicos-1-yl)oxy]-; 6,9,12,15,18,21-Hexaoxa-3-azatetracosan-24-oic acid, 1-bromo-2-oxo-
IUPAC Name	3-[2-[2-[2-[2-[2-[2-[(2-bromoacetyl)amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
Canonical SMILES	C(COCCOCCOCCOCCOCCOCCNC(=O)CBr)C(=O)O
InChI	InChI=1S/C17H32BrNO9/c18-15-16(20)19-2-4-24-6-8-26-10-12-28-14-13-27-11-9-25-7-5-23-3-1-17(21)22/h1-15H2,(H,19,20)(H,21,22)
InChIKey	AIMIPBWCWPFVBR-UHFFFAOYSA-N
Boiling Point	620.1±55.0°C (Predicted)
Purity	≥95%
Density	1.313±0.06 g/cm3 (Predicted)
Appearance	Pale Yellow or Colorless Oily Matter
Storage	Store at 2-8°C

BrCH2CONH-PEG6-acid, a highly versatile heterobifunctional polyethylene glycol (PEG) compound, finds widespread use in bioconjugation and pharmaceutical applications. Here are four key applications of BrCH2CONH-PEG6-acid, presented with elevated perplexity and burstiness:

Drug Delivery Systems: Playing a pivotal role in the realm of advanced drug delivery systems, BrCH2CONH-PEG6-acid's unique PEGylation capability enhances the solubility and stability of therapeutic compounds. By prolonging the half-life of these compounds in the bloodstream, it facilitates more effective drug delivery to specific tissues, ultimately improving patient outcomes to a significant degree.

Protein-Protein Crosslinking: Within the realm of protein-protein interactions, BrCH2CONH-PEG6-acid serves as an indispensable linker, enabling the study of intricate protein associations and functions. By bridging two proteins, researchers can stabilize complex structures and delve into their biological activities, shedding light on fundamental mechanisms in structural biology and biochemistry research, thus enriching our understanding of cellular processes.

Antibody-Drug Conjugates (ADCs): BrCH2CONH-PEG6-acid emerges as a cornerstone in the synthesis of antibody-drug conjugates, where its PEG linker facilitates the attachment of potent drugs to antibodies. This novel approach gives rise to targeted therapies that deliver cytotoxic agents specifically to cancer cells, minimizing off-target effects and augmenting therapeutic efficiency. ADCs represent a cutting-edge frontier in tailored cancer treatment strategies, poised to revolutionize personalized medicine.

Surface Modification: In the domain of biomaterial surface modification, BrCH2CONH-PEG6-acid emerges as a transformative agent, enhancing biocompatibility and mitigating immune responses. By coating medical devices with PEG, it effectively resists protein adsorption and cell adhesion, thereby reducing the likelihood of complications such as inflammation and infection. This pivotal role in improving the safety and efficacy of medical implants underscores its critical importance in advancing healthcare technologies to new heights.

Reviews

If you have any suggestions or comments about mPEG-Br, please submit a review immediately.